We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $6.05B
1-Year Est. Return 76.64%
This Fund
S&P 500
This Quarter Est. Return
-1.17%
1 Year Est. Return
+76.64%
3 Year Est. Return
+247.17%
5 Year Est. Return
+285.6%
10 Year Est. Return
+2,546.71%
AUM
$1.54B
AUM Growth
-$101M
Cap. Flow
-$61.8M
Cap. Flow %
-4.02%
Top 10 Hldgs %
28.17%
Holding
136
New
11
Increased
33
Reduced
22
Closed
8

Top Buys

Rank Stock Value
1
INST
Instructure, Inc.
INST
+$14.4M
2
WCN
Waste Connections
WCN
+$13.3M
3
W icon
Wayfair
W
+$12.6M
4
SNA icon
Snap-on
SNA
+$11.4M
5
DOOR
MASONITE INTERNATIONAL CORP
DOOR
+$6.18M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$18.9M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$16.6M
3
LRCX icon
Lam Research
LRCX
+$16.5M
4
WAB icon
Wabtec
WAB
+$15.7M
5
PANW icon
Palo Alto Networks
PANW
+$14.4M

Sector Composition

Rank Sector Weight
1 Healthcare 33.47%
2 Consumer Discretionary 15.87%
3 Technology 15.54%
4 Industrials 12.46%
5 Utilities 3.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
51
Acadia Pharmaceuticals
ACAD
$4.55B
$9.65M 0.63%
334,700
– –
STML
52
DELISTED
Stemline Therapeutics, Inc.
STML
$9.11M 0.59%
851,400
– –
XNCR icon
53
Xencor
XNCR
$1.59B
$9.05M 0.59%
344,000
– –
AYR
54
DELISTED
Aircastle Ltd
AYR
$8.94M 0.58%
428,600
– –
DBVT
55
DBV Technologies
DBVT
$817M
$8.77M 0.57%
24,960
– –
TSRO
56
DELISTED
TESARO, Inc.
TSRO
$8.74M 0.57%
65,000
-10,000
-13% -$1.26M
SAGE
57
DELISTED
Sage Therapeutics
SAGE
$8.68M 0.56%
170,000
– –
TSLA icon
58
Tesla
TSLA
$1.22T
$8.55M 0.56%
600,000
– –
ONCE
59
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$7.49M 0.49%
150,000
– –
BPMC
60
DELISTED
Blueprint Medicines
BPMC
$7.43M 0.48%
265,000
– –
GWPH
61
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$7.1M 0.46%
63,500
– –
EXR icon
62
Extra Space Storage
EXR
$31.3B
$6.29M 0.41%
81,500
+1,500
+2% +$110K
BMRN icon
63
BioMarin Pharmaceuticals
BMRN
$11.7B
$6.21M 0.4%
75,000
– –
RARE icon
64
Ultragenyx Pharmaceutical
RARE
$2.56B
$6.14M 0.4%
87,400
– –
ACRS icon
65
Aclaris Therapeutics
ACRS
$743M
$5.97M 0.39%
220,000
+80,000
+57% +$2.04M
PRTA icon
66
Prothena Corp
PRTA
$440M
$5.9M 0.38%
120,000
– –
CSLT
67
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$5.79M 0.38%
1,170,000
-538,600
-32% -$2.44M
KITE
68
DELISTED
Kite Pharma, Inc.
KITE
$5.74M 0.37%
128,000
-20,600
-14% -$1.01M
EPIX
69
DELISTED
ESSA Pharma
EPIX
$5.26M 0.34%
135,971
– –
CERN
70
DELISTED
Cerner Corp
CERN
$5.13M 0.33%
108,200
– –
NBIX icon
71
Neurocrine Biosciences
NBIX
$18.7B
$4.84M 0.31%
125,000
– –
ASND icon
72
Ascendis Pharma A/S
ASND
$16.5B
$4.63M 0.3%
+229,000
New +$4.57M
ALDR
73
DELISTED
Alder Biopharmaceuticals
ALDR
$4.47M 0.29%
+215,000
New +$5.59M
TCON
74
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$4.24M 0.28%
4,328
+1,739
+67% +$1.99M
BOLD
75
DELISTED
Audentes Therapeutics, Inc
BOLD
$4.11M 0.27%
225,000
– –
1 2
3
4 5

Similar funds

HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
RCG
Ruane, Cunniff & Goldfarb New York $6.03B AUM 12.06% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
CM
CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return

Eventide Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Eventide Asset Management held 136 positions worth $1.54B, down 6.2% from $1.64B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Eventide Asset Management withdrew a net $61.8M in Q4 2016, closing 8 positions and reducing 22 holdings. Its most notable exit was Ormat Technologies, an estimated $13.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Consumer Discretionary and Technology.

Against the trend, Eventide Asset Management opened a new position in Instructure, Inc. worth $13.1M.

  • Eventide Asset Management's largest Q4 2016 buy was Instructure, Inc.: 670,000 shares worth $13.1M.
  • Eventide Asset Management added most to Snap-on in Q4 2016, an estimated $11.4M increase.
  • Eventide Asset Management's biggest Q4 2016 reduction was Celgene Corp, cutting an estimated $18.9M.
  • Eventide Asset Management fully exited Ormat Technologies in Q4 2016, selling an estimated $13.4M.
  • Eventide Asset Management's ten largest holdings make up 28% of its $1.54B portfolio in Q4 2016.
  • Eventide Asset Management opened 11 new positions and closed 8 in Q4 2016.
  • Eventide Asset Management's portfolio value fell 6.2% quarter-over-quarter to $1.54B.

Based on Eventide Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.